TOP TEN perturbations for P04000 (Homo sapiens)

Organism: Homo sapiens
Gene: P04000
Selected probe(set): 221327_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of P04000 (221327_s_at) across 5610 perturbations tested by GENEVESTIGATOR:

rhegmatogenous retinal detachment study 1 / normal retina tissue

Relative Expression (log2-ratio):-1.5210104
Number of Samples:19 / 17
Experimental rhegmatogenous retinal detachment study 1
Retina tissue samples from patients with retinal detachment obtained by vitrectomy.
Control normal retina tissue
Postmortem retina tissue samples from healthy patients without any diseases of the eye.

influenza virus study 9 (A/pH1N1) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.190115
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/pH1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype [A/Singapore/478/2009 (pH1N1)]. Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-0.98289204
Number of Samples:3 / 3
Experimental influenza virus study 11 (A/H5N3)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

influenza virus study 9 (A/H9N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-0.8733387
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/H9N2)
Human carcinoma cell line A549 infected with influenza A virus subtype A/Duck/Malaysia/01 (H9N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

HIF-1a/HIF-2a depletion study 1 (hypoxia; AB81) / hypoxia study 11 (AB81)

Relative Expression (log2-ratio):-0.7996721
Number of Samples:3 / 3
Experimental HIF-1a/HIF-2a depletion study 1 (hypoxia; AB81)
Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with hypoxia (1% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates.
Control hypoxia study 11 (AB81)
Human podocyte cell line AB81 treated with hypoxia (1% O2) for 24 hours. Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates.

influenza virus study 10 (A/H5N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-0.7762947
Number of Samples:3 / 3
Experimental influenza virus study 10 (A/H5N2)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F189/07/2004(H5N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

strabismus study 1 / normal extraocular medial rectus muscle tissue

Relative Expression (log2-ratio):-0.7416582
Number of Samples:3 / 4
Experimental strabismus study 1
Human extraocular medial rectus muscle tissue sample obtained from patients with strabismus after strabismus correction surgery.
Control normal extraocular medial rectus muscle tissue
Postmortem human extraocular medial rectus tissue samples from healthy donors without any ophthalmologic disease.

psoriasis study 24 (lesional; ustekinumab; 1wk; 45mg; non-responder) / psoriasis study 24 (lesional; etanercept; 1wk; 50mg; non-responder)

Relative Expression (log2-ratio):-0.7221594
Number of Samples:2 / 12
Experimental psoriasis study 24 (lesional; ustekinumab; 1wk; 45mg; non-responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at 1 week after treatment with 45 mg ustekinumab and assigned as non-responders. Ustekinumab was administered subcutaneously in dose of 45 mg at week 0. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT. ATC code:
Control psoriasis study 24 (lesional; etanercept; 1wk; 50mg; non-responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at 1 week after treatment with 50 mg etanercept and assigned as non-responders. Etanercept was administered subcutaneously in dose of 50 mg twice weekly. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT. ATC code:

influenza virus study 4 (A/H1N1) / mock infected A549 cell sample

Relative Expression (log2-ratio):0.692997
Number of Samples:3 / 6
Experimental influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.
Control mock infected A549 cell sample
Human A549 carcinoma cells mock infected (A/H1N1). Sample was taken at 0 hours post-infection.

psoriasis study 24 (lesional; baseline; ustekinumab; 90mg; non-responder) / psoriasis study 24 (non-lesional; baseline; ustekinumab; 90mg; non-responder)

Relative Expression (log2-ratio):0.6870432
Number of Samples:10 / 9
Experimental psoriasis study 24 (lesional; baseline; ustekinumab; 90mg; non-responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with 90 mg ustekinumab) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.
Control psoriasis study 24 (non-lesional; baseline; ustekinumab; 90mg; non-responder)
Non-lesional and macroscopic normal skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with 90 mg ustekinumab) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Patients participated in a phase 3 of Psoriasis Trial ACCEPT.